Abiraterone Acetate
Code | Size | Price |
---|
TAR-T6215-10mg | 10mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6215-1mL | 1 mL * 10 mM (in DMSO) | £115.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6215-50mg | 50mg | £119.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6215-100mg | 100mg | £134.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6215-500mg | 500mg | £229.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Abiraterone acetate is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
CAS:
154229-18-2
Formula:
C26H33NO2
Molecular Weight:
391.555
Pathway:
Metabolism
Purity:
0.9989
SMILES:
CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1
Target:
P45
References
Zhang X, Cheng L, Gao C, et al.Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-?B Activation in T Cells and Suppressing Anti-Tumor Immunity.Cancer Research.2023
Li R, et al. Clin Cancer Res. 2012, 18(13), 3571-3579.
Duc I, et al. J Steroid Biochem Mol Biol. 2003, 84(5), 537-542.
Pinto-Bazurco Mendieta MA, et al. J Med Chem. 2008, 51(16), 52009-52018.
Rice M A, Kumar V, Tailor D, et al. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Reports Medicine. 2022: 100502.
Richards J, et al. Cancer Res. 2012, 72(9), 2176-2182.